Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
ACS Nano|July 26, 2024
Promoting Proton Donation through Hydrogen Bond Breaking on Carbon Nitride for Enhanced H2O2 PhotosynthesisYao Lu, Yanzhen Guo, Shao Zhang, et al.
ACS Applied Materials & Interfaces|November 18, 2022
Tipping Gold Nanobipyramids with Titania for the Use of Plasmonic Hotspots to Drive Amine CouplingGuangli He, Yunhe Lai, Yanzhen Guo, et al.
Journal of Colloid and Interface Science|February 15, 2020
A Z-scheme photocatalyst for enhanced photocatalytic H2 evolution, constructed by growth of 2D plasmonic MoO3-x nanoplates onto 2D g-C3N4 nanosheetsYanzhen Guo, Binbin Chang, Ting Wen, et al.
ACS Applied Materials & Interfaces|April 28, 2021
Selective Deposition of Catalytic Metals on Plasmonic Au Nanocups for Room-Light-Active Photooxidation of o-PhenylenediamineHan Zhang, Shiu Hei Lam, Yanzhen Guo, et al.
ACS Applied Materials & Interfaces|June 13, 2025
Dual-Functional Schottky-Barrier-Free Plasmonic TiN/TiO2 Photocatalyst for Efficient NH3 and H2 ProductionXiaopeng Bai, Ke An, Lingyu Jia, et al.
Signal Transduction and Targeted Therapy|November 7, 2024
First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 studyNing Li, Jin Xia, Xiaohui Gao, et al.
BMC Cancer|March 18, 2025
Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 studyYuankai Shi, Xinshuai Wang, Zhidong Pei, et al.
The Lancet. Gastroenterology & Hepatology|January 9, 2022
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trialXiangrui Meng, Tao Wu, Yonggui Hong, et al.
Annals of Translational Medicine|January 20, 2023
Apatinib in the treatment of gastric cancer in Henan Province: a multicenter prospective real-world observational study (Ahead-HAP01)Yijie Ma, Weijie Zhao, Peichun Sun, et al.
JAMA Oncology|February 8, 2024
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence TrialShaohua Zhang, Yongmei Yin, Hailin Xiong, et al.
Pageof 4